Jagsonpal Pharmaceuticals Limited has released the transcript for its Q3 FY26 Earnings Conference Call, which was held on January 22, 2026. The call featured discussions on the company's financial results for the third quarter and the nine-month period of FY26. During the call, management acknowledged that the Q3 performance was "flattish" and below expectations, attributing it partly to headwinds in their RPM (Relevant Product Mix) segment and strategic reviews under new leadership aimed at improving long-term growth. However, on a nine-month basis, the company reported a resilient performance with 6% top-line growth and a 13% improvement in the bottom line. The management expressed confidence in achieving double-digit growth starting from Q4 FY26. Key financial highlights for Q3 FY26 included revenue of ₹73 crore, EBITDA of ₹16.7 crore (22.7% margin), and PAT of ₹12.5 crore (17.1% margin), showing a 10% year-on-year growth. For the nine-month period, revenue grew by 6% to ₹223 crore, EBITDA increased by 5% to ₹50.3 crore, and PAT grew by 12.5% to ₹35.9 crore. The company also noted a one-time past service cost of ₹2.1 crore related to the new labor code. Strategic priorities discussed included strengthening the leadership team with the appointment of Amrut Medhekar as COO and Nirav Vora as CFO, focusing on growth drivers like orthopedics and women's health, empowering teams, and optimizing field operations. The company is also looking at potential M&A opportunities and considering returning excess cash to shareholders if suitable acquisitions are not found. Management expressed optimism about doubling industry growth in the coming quarters and achieving a sustainable double-digit organic growth over the next three to four years.
